Ignite Creation Date:
2024-05-06 @ 1:31 AM
Last Modification Date:
2024-10-26 @ 11:05 AM
Study NCT ID:
NCT01828112
Status:
COMPLETED
Last Update Posted:
2023-11-30
First Post:
2013-04-02
Brief Title:
LDK378 Versus Chemotherapy in ALK Rearranged ALK Positive Patients Previously Treated With Chemotherapy Platinum Doublet and Crizotinib
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Non-Small Cell Lung Cancer |
Keywords:
| Name | View |
|---|---|
| crizotinib | View |
| Non-Small Cell Lung Cancer | View |
| ALK | View |
| LDK378 | View |
| Non-small cell lung carcinoma NSCLC | View |
| treatment of lung cancer after first metastasis | View |
| lung cancer | View |
| lung adenocarcinoma | View |
| Non small cell lung carcinoma | View |
| Non small cell lung cancer | View |
| NSCLC | View |
| chemotherapy | View |
| ALK-positive | View |
| ALK-rearranged advanced non-small cell lung cancer | View |